2005
DOI: 10.1128/jvi.79.13.8217-8229.2005
|View full text |Cite
|
Sign up to set email alerts
|

An Interplay between Hypervariable Region 1 of the Hepatitis C Virus E2 Glycoprotein, the Scavenger Receptor BI, and High-Density Lipoprotein Promotes both Enhancement of Infection and Protection against Neutralizing Antibodies

Abstract: Hepatitis C virus (HCV) circulates in the bloodstream in different forms, including complexes with immunoglobulins and/or lipoproteins.To address the significance of such associations, we produced or treated HCV pseudoparticles (HCVpp), a valid model of HCV cell entry and its inhibition, with naïve or patient-derived sera. We demonstrate that infection of hepatocarcinoma cells by HCVpp is increased more than 10-fold by human serum factors, of which high-density lipoprotein (HDL) is a major component. Infection… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

26
327
3
10

Year Published

2005
2005
2020
2020

Publication Types

Select...
5
2

Relationship

0
7

Authors

Journals

citations
Cited by 264 publications
(366 citation statements)
references
References 53 publications
26
327
3
10
Order By: Relevance
“…The antiviral activity of SAA was therefore tested in the presence of normal human serum. As described, 10 the addition of 1% normal human serum during infection resulted in approximately a 3-fold increase of HCVpp infectivity (Fig. 6A).Although the addition of SAA at a concentration of 15 g/mL inhibited HCVpp infectivity by more than 90% in the presence of LPDS, this antiviral effect was strongly attenuated in the presence of human serum.…”
Section: Antiviral Activity Of Saa Can Be Attenuated In the Presence supporting
confidence: 62%
See 2 more Smart Citations
“…The antiviral activity of SAA was therefore tested in the presence of normal human serum. As described, 10 the addition of 1% normal human serum during infection resulted in approximately a 3-fold increase of HCVpp infectivity (Fig. 6A).Although the addition of SAA at a concentration of 15 g/mL inhibited HCVpp infectivity by more than 90% in the presence of LPDS, this antiviral effect was strongly attenuated in the presence of human serum.…”
Section: Antiviral Activity Of Saa Can Be Attenuated In the Presence supporting
confidence: 62%
“…HCVpp were obtained for genotypes 1a, 1b, 2a, 2b, 3a and 4. Virus entry was measured as in lipid-transfer function of SR-BI has been shown to affect HCVpp infectivity in the presence of HDL, 10,12 we wondered whether SAA-mediated cholesterol efflux might play a role in inhibition of HCV entry. If SAA-mediated cholesterol efflux is responsible for entry inhibition, treating target cells with BLT1, a drug that inhibits SR-BIdependent cholesterol efflux, 26 should therefore restore HCVpp infectivity when infection is performed in the presence of SAA.…”
Section: Saa Inhibits Hcv Entry Into Huh-7 Cellsmentioning
confidence: 99%
See 1 more Smart Citation
“…Anti-E1/E2 Abs [9,11,62,148], patient sera [9], soluble E2 [46], lectins [150,151], anti-ApoE antibodies [29], apoE peptides [149] Abs, Erlotinib, Lapatinib, Gefitinib [141] EGF, TGF-α [141] HDL [138] ApoCI [139] BLTs [138,140] Abs, Dasatinib [141] Arbidol [144] Abs [109,137], ITX 5061 [134], natural ligands [135,136] Abs, soluble CD81 [9,11] Abs [142] Cldn1 peptide [143] Heparin, GAG nzymatic digestion [69,132] Abs, natural ligands, soluble LDL receptor [30,133] GAGs LDLR CD81 SR-BI Cldn1 Ocln…”
Section: Epha2mentioning
confidence: 99%
“…Anti-E1/E2 Abs [9,11,62,148], patient sera [9], soluble E2 [46], lectins [150,151], anti-ApoE antibodies [29], apoE peptides [149] Abs, Erlotinib, Lapatinib, Gefitinib [141] EGF, TGF-α [141] HDL [138] ApoCI [139] BLTs [138,140] Abs, Dasatinib [141] Arbidol [144] …”
Section: Epha2mentioning
confidence: 99%